The clinical role of VeriStrat testing in patients with advanced non–small cell lung cancer considered unfit for first-line platinum-based chemotherapy()

PURPOSE: We previously demonstrated that the median survival of patients with poor prognosis non–small cell lung cancer (NSCLC) considered unfit for first-line platinum chemotherapy was <4 months. We evaluated whether VeriStrat could be used as a prognostic or predictive biomarker in this populat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Siow Ming, Upadhyay, Sunil, Lewanski, Conrad, Falk, Stephen, Skailes, Geraldine, Woll, Penella J., Hatton, Matthew, Lal, Rohit, Jones, Richard, Toy, Elizabeth, Rudd, Robin, Ngai, Yenting, Edwards, Alex, Hackshaw, Allan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Ltd 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859789/
https://www.ncbi.nlm.nih.gov/pubmed/31499384
http://dx.doi.org/10.1016/j.ejca.2019.07.025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859789/
https://www.ncbi.nlm.nih.gov/pubmed/31499384
http://dx.doi.org/10.1016/j.ejca.2019.07.025

Ejemplares similares